- Home
- CERS vs AVIR Comparison
CERS vs AVIR Comparison
Compare CERS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- AVIR
- Stock Information
- Founded
- CERS 1991
- AVIR 2012
- Country
- CERS United States
- AVIR United States
- Employees
- CERS N/A
- AVIR N/A
- Industry
- CERS EDP Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CERS Technology
- AVIR Health Care
- Exchange
- CERS Nasdaq
- AVIR Nasdaq
- Market Cap
- CERS 271.4M
- AVIR 275.6M
- IPO Year
- CERS 1997
- AVIR 2020
- Fundamental
- Price
- CERS $1.34
- AVIR $3.25
- Analyst Decision
- CERS Strong Buy
- AVIR Hold
- Analyst Count
- CERS 2
- AVIR 1
- Target Price
- CERS $3.50
- AVIR $6.00
- AVG Volume (30 Days)
- CERS 1.4M
- AVIR 402.4K
- Earning Date
- CERS 07-31-2025
- AVIR 08-06-2025
- Dividend Yield
- CERS N/A
- AVIR N/A
- EPS Growth
- CERS N/A
- AVIR N/A
- EPS
- CERS N/A
- AVIR N/A
- Revenue
- CERS $185,144,000.00
- AVIR N/A
- Revenue This Year
- CERS $24.95
- AVIR N/A
- Revenue Next Year
- CERS $8.48
- AVIR N/A
- P/E Ratio
- CERS N/A
- AVIR N/A
- Revenue Growth
- CERS 13.06
- AVIR N/A
- 52 Week Low
- CERS $1.12
- AVIR $2.46
- 52 Week High
- CERS $2.54
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- CERS 48.75
- AVIR 63.83
- Support Level
- CERS $1.29
- AVIR $3.15
- Resistance Level
- CERS $1.41
- AVIR $3.35
- Average True Range (ATR)
- CERS 0.10
- AVIR 0.13
- MACD
- CERS -0.01
- AVIR 0.00
- Stochastic Oscillator
- CERS 27.27
- AVIR 73.24
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).